Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid

Related Keywords

Japan ,Tokyo ,Kawauchi ,Miyagi ,United States ,Texas ,Vancouver ,British Columbia ,Canada ,Beijing ,China ,Tokushima ,Japanese ,Kiyoshi Eshima ,Yasuo Matsueda ,Head Office ,Drug Administration ,Md Anderson Cancer Center ,Fly Pharma Inc ,Branch Office ,Delta Fly Pharma ,Orphan Drug Designation ,Acute Myeloid Leukemia ,Cancer Center ,Hematologic Cancer Treatment ,Fly Pharma ,Japanese Yen ,Delta ,Dharma ,Granted ,Orphan ,Drug ,Resignation ,Wood ,Administration ,0917 ,